Adding Relacorilant To Nab-paclitaxel Prolongs Survival Compared with a Weekly Taxane in Patients with Platinum-Resistant Epithelial Ovarian Cancer By Ogkologos - June 23, 2025 613 0 Facebook Twitter Google+ Pinterest WhatsApp Findings from the ROSELLA study Source RELATED ARTICLESMORE FROM AUTHOR Low-Dose Pembrolizumab with Dose-Dense Chemotherapy Increases pCR as Neoadjuvant Treatment for Localised TNBC ESMO Advocates for Equal Access to Optimal Cancer Care for all Patients with Cancer at the 79th World Health Assembly Daraxonrasib Shows Antitumour Activity Among Patients with Previously Treated RAS-mutated Pancreatic Ductal Adenocarcinoma MOST POPULAR Drug Combination May Have Potential for Cancers with TP53 Mutations April 4, 2024 FDA Approves Pembrolizumab for Adjuvant Treatment of Stage IIB or IIC... December 7, 2021 FDA Grants Accelerated Approval to Melphalan Flufenamide for Relapsed or Refractory... April 20, 2021 Lo que debe saber sobre el cáncer de pulmón October 16, 2020 Load more HOT NEWS Targeting FGFR1 in Patients with Tumour-Induced Osteomalacia 40 K9 Officers Line Up Outside Terminally Ill Girl’s House For... Bride Diagnosed with Stage IV Triple-Negative Breast Cancer 6 Months Before... Blinatumomab Boosts Chemotherapy as Initial Treatment for Some Kids with ALL
